Nottingham pharma firm swoops for US rival in eight-figure deal

Quotient Clinical, the Ruddington-based drug development company, has acquired SeaView Research in an eight-figure deal.

The deal, the exact value of which is disclosed, sees Quotient expanding its operations into the USA and will see the firms combine their customer portfolios.

SeaView was founded in 1995, with 160 employees across two clinical pharmacology units located in Miami and Jacksonville, Florida, and a combined bed capacity of 320.

Mark Egerton, chief executive officer, Quotient, said: “Establishing an operational footprint in the US is an important milestone in the development of our business. We can now offer our customers the option to undertake their early phase clinical research either in the UK or the USA, and the acquisition of SeaView is a key component of our plan to replicate our Translational Pharmaceutics platform in the USA.”

Stuart Harris and Celina Alvarez, co-founders of SeaView, said: “We are excited to join forces with Quotient and are looking forward to working together to continue growing the business. The combination of the Quotient and SeaView businesses enables us to deliver full service support to our customers, and the market potential for Translational Pharmaceutics in the USA is significant.”